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Bosma arhinia microphthalmia syndrome (BAMS) is an 
extremely rare and striking condition characterized by 
complete absence of the nose with or without ocular defects. 
We report here that missense mutations in the epigenetic 
regulator SMCHD1 mapping to the extended ATPase domain of 
the encoded protein cause BAMS in all 14 cases studied.  
All mutations were de novo where parental DNA was available. 
Biochemical tests and in vivo assays in Xenopus laevis embryos 
suggest that these mutations may behave as gain-of-function 
alleles. This finding is in contrast to the loss-of-function 
mutations in SMCHD1 that have been associated with 
facioscapulohumeral muscular dystrophy (FSHD) type 2.  
Our results establish SMCHD1 as a key player in nasal development 
and provide biochemical insight into its enzymatic function that 
may be exploited for development of therapeutics for FSHD. 
Congenital absence of the nose (arhinia) is a rare and striking 
condition with fewer than 50 patients reported thus far1. Arhinia 
is variably associated with absent paranasal sinuses, hypertelorism, 
microphthalmia, colobomas, nasolacrimal duct abnormalities, mid-
face hypoplasia, high-arched palate, absent olfactory bulbs and defects 
of the reproductive axis in males. In its most severe presentation, 
consisting of nasal, ocular and reproductive defects, it is referred to 
as BAMS (MIM 603457)1,2. Arhinia is presumed to result from a spe-
cific defect in the nasal placodes or surrounding neural crest–derived 
tissues during embryonic development, but a genetic cause has not 
been established.
We investigated 14 unrelated individuals with isolated arhinia 
or a syndromic presentation compatible with BAMS (Fig. 1a–l, 
Supplementary Fig. 1 and Supplementary Table 1). Trio or quartet 
whole-exome sequencing for cases 1, 2 and 9–12 led to the identifi-
cation of de novo heterozygous missense mutations in the SMCHD1 
gene (encoding structural maintenance of chromosomes flexible 
hinge domain containing 1; NM_015295.2) in all six cases (Fig. 1m, 
Table 1 and Supplementary Table 2), which were confirmed by 
Sanger sequencing (Supplementary Fig. 2). Singleton whole-exome 
sequencing for case 13 also identified an SMCHD1 mutation. We then 
performed Sanger sequencing of SMCHD1 in the seven remaining 
patients with BAMS. Heterozygous missense mutations were identi-
fied in all. In total, 11 of the 14 variants were de novo, suggesting 
germline mutations in parental gametes, while in three cases parental 
DNA was not available (Table 1 and Supplementary Fig. 2). None of 
the identified mutations have been reported in the Exome Aggregation 
Consortium (ExAC), Exome Variant Server (EVS) or dbSNP144 data-
base (accessed via the UCSC Genome Browser, November 2016), all 
mutations affected highly conserved residues (Supplementary Fig. 3) 
and all were predicted to be damaging by PolyPhen-2 (Table 1). All 14 
mutations are located in exons 3, 8–10, 12 or 13 of SMCHD1 (48 exons 
in total); these exons encode the ATPase domain of SMCHD1 and 
an associated region immediately C terminal to it. Notably, 6 of the 
14 patients had mutations that affected three adjacent amino acids—
Ala134, Ser135 and Glu136—while p.His348Arg and p.Asp420Val 
were identified in three and two independent patients each, suggest-
ing possible mutational hotspots (Fig. 1m). Mutations in SMCHD1 in 
individuals with arhinia have also been identified in an independent 
study that included six of the cases analyzed here (cases 2, 4–7 and 13; 
see the accompanying manuscript3).
During craniofacial development, the olfactory placode ectoderm 
thickens and invaginates to form the olfactory epithelium within the 
nasal cavity, a process that depends on crosstalk between the placodal 
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epithelium and the underlying cranial neural crest–derived mesen-
chyme4. For example, ablation of the nasal placode epithelium in 
chick embryos disrupts the development of adjacent nasal skeletal 
elements5. We observed strong X-gal (5-bromo-4-chloro-3-indolyl-
β-d-galactopyranoside) staining in the developing face of mouse 
embryos expressing lacZ from the Smchd1 locus6, including in the 
nasal placodes and optic vesicles at embryonic day (E) 9.5 and in 
the nasal epithelium at E12.5 (Supplementary Fig. 4). Eurexpress 
in situ hybridization data indicate regional expression of Smchd1 in the 
nasal cavity in E14.5 mice, while transcriptional profiling of postnatal 
olfactory epithelium demonstrated that Smchd1 is specifically 
expressed in immature olfactory sensory neurons7. These data are 
consistent with roles for SMCHD1 during early nasal development. 
Gonadotropin-releasing hormone (GnRH) neurons migrate from 
the olfactory placode along olfactory axon tracts to the hypothala-
mus, where they regulate reproductive hormone release from the 
pituitary gland. Defects in the reproductive axis have occasionally 
been reported in males with arhinia1,2,8; we confirm this finding and 
Q193Rfs*36 E532* P1335Lfs*18 V1514Gfs*7
2,0051
1,8751,688
SMC hinge
365111
GHKL ATPase
N-terminal region
k l
ba
R552Q
K518E
D420V
D420V
H348R
H348R
H348R
W342S
E136G
S135N
S135C
S135C
A134S
A134S
ji
hgfe
dc
m
702
Figure 1 SMCHD1 is mutated in Bosma arhinia microphthalmia syndrome and isolated arhinia. (a,b) Case 1. (c,d) Case 12. (e) Case 3. (f) Case 9.  
(g) Case 10. (h) Case 6. (i–l) Case 11, with a forehead implant (rectangular box) in preparation for rhinoplasty (j), 6 months after the operation  
(k) and in a computed tomography scan of the skull before the operation (l). Consent was obtained to publish patient images. (m) Positions of  
BAMS-associated missense variants (black) and heterozygous loss-of-function variants from ExAC (red) in SMCHD1. Short bars represent known 
missense (purple) and frameshift or nonsense (red) FSHD2-associated variants. See supplementary Figure 3 for details on the exact amino acids 
mutated in FSHD2 in the N-terminal region.
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also report pubertal delay or anomalies of menarche in all three 
post-pubertal females in our series (Supplementary Table 1). The 
reproductive axis defects associated with arhinia are likely second-
ary to a defect in GnRH neuron production in or migration from the 
olfactory placode.
Smchd1 was identified as a modifier of transgene silencing in mice and 
was subsequently shown to be involved in X-chromosome inactivation, 
where it is required for CpG island (CGI) methylation on the inactive 
X chromosome, CGI-independent silencing of some X-chromosome 
genes and compaction of the inactive X chromosome6,9–11. In addi-
tion, Smchd1 functions as an epigenetic repressor at various autosomal 
loci, with dysregulation of imprinted and monoallelically expressed 
gene clusters observed in mice mutant for Smchd110,12,13. A require-
ment for SMCHD1 in the repair of DNA double-strand breaks has 
also been demonstrated14,15. Whereas female mice null for Smchd1 
display midgestation lethality due to derepression of genes on the inac-
tive X chromosome, male mutant mice display perinatal lethality of 
undescribed causes in certain strains or viability on the FVB/n back-
ground12. Strikingly, craniofacial abnormalities have not been docu-
mented in mice with Smchd1 loss of function regardless of their sex.
Recently, haploinsufficiency for SMCHD1 was reported as a cause 
of FSHD type 2 (FSHD2; MIM 158901)16. FSHD has a prevalence of 
1 in 20,000, with FSHD type 1 (FSHD1) and FSHD2 accounting for 
~95% and ~5% of cases, respectively17. FSHD results from patho-
genic misexpression of the transcription factor DUX4 (encoded by 
an array of D4Z4 repeats on chromosome 4q) in skeletal muscle. In 
FSHD1 (MIM 158900), D4Z4 repeat contraction leads to hypometh-
ylation of the locus and derepression of DUX4 expression on a per-
missive haplotype (4qA) that harbors a stabilizing polyadenylation 
signal for DUX4 mRNA17,18. FSHD2 occurs in individuals harboring 
loss-of-function SMCHD1 mutations and the permissive 4qA allele, 
without the requirement for D4Z4 repeat contraction, although 
SMCHD1 mutations can also modify the severity of FSHD1 (refs. 
16,19). SMCHD1 is thought to function as a silencer at the 4q locus 
via binding to the D4Z4 repeats16. Over 80 unique, putatively patho-
genic SMCHD1 variants have been reported in patients with FSHD2 
(LOVD SMCHD1 variant database; see URLs). These mutations, 
which include clear loss-of-function alleles, map throughout the 
protein and are not clustered in specific domains. Several loss-of-
function mutations have also been reported in the ExAC database 
(Fig. 1m), and over 60 deletions affecting SMCHD1 have been 
reported in the DECIPHER database (available phenotypic informa-
tion does not indicate occurrence of arhinia in deletion carriers). 
We analyzed the methylation status of D4Z4 repeats in peripheral 
blood leukocytes from patients with BAMS by sodium bisulfite 
sequencing (Supplementary Figs. 5–7 and Supplementary Table 3). 
Although a trend for hypomethylation was noted for patients with 
BAMS relative to controls or their unaffected family members, 
depending on the site tested within the D4Z4 repeat, some patients 
with BAMS were normally methylated. A large variability in D4Z4 
methylation has also been observed in controls and patients with 
FSHD20, and altered methylation is not an absolute indicator of FSHD. 
Moreover, an important argument against BAMS- and FSHD2-asso-
ciated mutations acting in the same direction is the absence in the 
literature (to our knowledge) of reports of BAMS and FSHD co-occur-
ring in the same patient. None of the patients with BAMS reported 
here have signs of muscular dystrophy, including both the individuals 
(cases 2 and 12) older than the average age of onset for FSHD2 of 26 
years21, and none of the BAMS-associated missense mutations identi-
fied here have been linked to FSHD2.
Proteins of the SMC family are involved in chromatid cohesion, 
condensation of chromosomes and DNA repair. SMCHD1 is consid-
ered to be a non-canonical member of the family, with a C-terminal 
chromatin-binding hinge domain and an N-terminal GHKL (gyrase, 
Hsp90, histidine kinase and MutL) ATPase domain22 (Fig. 1m). 
SMCHD1 may potentially use energy obtained from ATP hydroly-
sis to manipulate chromatin ultrastructure and interactions. Using 
small-angle X-ray scattering, the purified recombinant mouse 
Smchd1 ATPase domain and an adjacent C-terminal region (amino 
acids 111–702 for the two regions combined; denoted N-terminal 
region in Fig. 1m) have been shown to adopt a structural confor-
mation similar to that of Hsp90 (ref. 22). Consistent with this, the 
Hsp90 inhibitor radicicol decreases the ATPase activity of Smchd1 
(refs. 22,23). Mapping of the SMCHDI amino acids mutated in BAMS 
and FSHD2 to the homology model of Smchd1 on the basis of the 
Hsp90 crystal structure indicates that the major cluster of variants 
in BAMS (amino acids 134–136) is situated immediately N terminal 
to motif I, which is highly conserved among the GHKL ATPases and 
participates in coordination of the Mg2+–ATP complex during ATP 
hydrolysis24 (Supplementary Figs. 3 and 8). The finding of other 
BAMS-associated mutations that map to the region immediately C 
terminal to the ATPase domain supports the idea that this extended 
table 1 SMCHD1 mutations identified in patients 1–14
Case Geographical origin Nucleotide changea Amino acid change
Predicted functional  
effectb Mutation origin
1 Morocco c.407A>G p.Glu136Gly 0.999 De novo
2* Germany c.403A>T p.Ser135Cys 1.000 De novo
3 North Africa c.404G>A p.Ser135Asn 0.997 De novo
4* Ireland c.403A>T p.Ser135Cys 1.000 De novo
5* China c.1043A>G p.His348Arg 0.998 De novo
6* Scotland c.1259A>T p.Asp420Val 0.877 De novo
7* Japan c.1655G>A p.Arg552Gln 1.000 De novo
8 Wales c.1552A>G p.Lys518Glu 0.976 Unknown (parental DNA unavailable)
9 Thailand c.1259A>T p.Asp420Val 0.877 De novo
10 Thailand c.1025G>C p.Trp342Ser 0.999 De novo
11 Turkey c.400G>T p.Ala134Ser 0.999 De novo
12 Turkey c.400G>T p.Ala134Ser 0.999 De novo
13* Norway c.1043A>G p.His348Arg 0.998 Unknown (parental DNA unavailable)
14 Ukraine c.1043A>G p.His348Arg 0.998 Unknown (parental DNA unavailable)
Individuals also studied by Shaw et al.3 are indicated with an asterisk.
aGiven with respect to reference sequence NM_015295.2. bBased on PolyPhen-2 score using UniProtKB identifier A6NHR9.
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region has a function intimately associated with that of the ATPase 
domain. Given that (i) loss of function of SMCHD1 causes FSHD2, 
(ii) FSHD is not known to co-occur with arhinia, (iii) there are no 
visible craniofacial anomalies in Smchd1-null mice, (iv) the mutations 
in patients with BAMS are clustered in the extended ATPase domain 
and (v) in contrast to SMCHD1 depletion14,15, BAMS-associated 
mutations do not cause alterations of the DNA damage response or 
impaired non-homologous end joining (Supplementary Fig. 9), we 
hypothesized that the mutations in BAMS might result in a gain rather 
than a loss of function for the SMCHD1 protein. To test this hypoth-
esis, we conducted ATPase assays using the purified recombinant 
N-terminal region of mouse Smchd1 harboring BAMS- or FSHD2-
associated alterations. In comparison to wild-type protein, the N-ter-
minal region containing the p.Ala134Ser, p.Ser135Cys or p.Glu136Gly 
substitution had increased protein hydrolysis of ATP, whereas the 
FSHD2 substitutions p.Tyr353Cys16 and p.Thr527Met19 resulted in 
strongly and slightly decreased ATPase activity, respectively; activity 
was unchanged with the BAMS-associated substitution p.Asp420Val 
(Fig. 2). The half-maximal inhibitory concentration (IC50) of 
radicicol was similar for the ATPase activities of the BAMS-associ-
ated mutant and wild-type recombinant proteins (Supplementary 
Fig. 10), suggesting that the mutants retain an intact ATP-binding 
site. These results suggest that BAMS-associated mutations increase 
the catalytic activity of SMCHD1.
We next sought to validate these biochemical results in vivo using 
full-length SMCHD1 protein. In Xenopus, the expression of smchd1 
begins zygotically and increases steadily after gastrulation (Fig. 3a). 
Endogenous smchd1 expression is strongly enriched in the head region 
and the neural tube (Fig. 3b). To faithfully recapitulate this expres-
sion pattern, the two dorsal–animal blastomeres of eight-cell-stage 
Xenopus embryos were microinjected with 120 pg of capped mRNA 
encoding either wild-type or mutant human SMCHD1 (Fig. 3c). 
Each set of injected embryos was checked to ensure expression of 
human SMCHD1 protein (Fig. 3g and Supplementary Fig. 11). Only 
tadpoles overexpressing SMCHD1 mRNA with BAMS-associated 
mutations showed noticeable craniofacial anomalies (Fig. 3d–f and 
Supplementary Fig. 12), including microphthalmia and, in severe 
cases, anophthalmia (Fig. 3f, right). At 4 days post-fertilization (d.p.f.), 
quantification of eye size showed a marked reduction in the diame-
ter of the eye in tadpoles overexpressing BAMS-associated mutants, 
whereas tadpoles overexpressing wild-type SMCHD1 or Tyr353Cys 
SMCHD1, an FSHD2-associated mutant, were indistinguishable from 
control, uninjected embryos (Fig. 3h). One of the BAMS-associated 
mutants with phenotypic effects in this assay, Asp420Val, showed 
no change in ATPase activity in vitro (Fig. 2), suggesting that the 
in vivo assay has higher sensitivity. Whole-mount in situ hybridi-
zation showed a decrease in the size of the eye and nasal placodes, 
marked by rx2a and six1 expression, respectively, upon overexpres-
sion of a BAMS-associated mutant (Fig. 3i,j). In contrast, migration 
of cranial neural crest, marked by twist1 expression, was largely unaf-
fected. Development of craniofacial anomalies was dose dependent in 
injections with wild-type SMCHD1 or a BAMS-associated mutant, 
whereas overexpression of the FSHD2 mutant Tyr353Cys did not have 
an effect, regardless of dose (Fig. 3k and Supplementary Fig. 12). 
The finding that wild-type SMCHD1, when overexpressed at a suffi-
ciently high concentration, acts in the same phenotypic direction as the 
BAMS-associated mutants suggests that these mutants may, at least in 
part, act by augmenting the normal activity of the protein. These in vivo 
results, which partially recapitulate the microphthalmia and facial hypo-
plasia seen in human patients with severe BAMS, further support the 
notion that, in contrast to FSHD2 alleles, BAMS-associated missense 
mutations may exhibit gain-of-function or neomorphic activity. We have 
not formally excluded the possibility that BAMS-associated mutants 
may behave as dominant negatives through heterodimerization with 
wild-type protein. However, we believe that this is unlikely, given the 
effects described above for overexpressed wild-type SMCHD1 and the 
finding that the isolated ATPase domain containing BAMS-associated 
variants can increase ATPase activity by itself (Fig. 2). In addition, 
a human phenotype associated with a dominant-negative mutation 
would be expected to present as a more severe disease than that asso-
ciated with haploinsufficiency of the same gene, with at least some 
phenotypic overlap, but this is not the case for BAMS and FSHD.
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Figure 2 Biochemical assays indicate that BAMS-associated SMCHD1 
mutants have increased ATPase activity. (a–e) ATPase assays performed 
using recombinant protein encompassing amino acids 111–702 of 
mouse Smchd1. Results are shown for wild-type (a), Ala134Ser (b), 
Ser135Cys (c), Glu136Gly (d) and Tyr353Cys (e) Smchd1. The amount 
of ADP produced at each protein concentration (0.1, 0.2, 0.4 and 0.6 
µM) and ATP concentration (1, 2.5, 5 and 10 µM) was measured as 
described in the Online Methods. Data are displayed as the means ± s.d. 
of three technical replicates. Each plot is representative of at least two 
independent experiments using different batches of protein preparation. 
(f) Relative ATPase activities of the mutant proteins in comparison to  
wild-type protein. The amount of ADP produced by the mutant proteins  
was normalized to that produced by wild-type protein at each protein  
and substrate concentration as in a–e. Normalized values are plotted  
as the means ± s.d. from two independent experiments (n = 44 for 
Ala134Ser, n = 24 for Ser135Cys, n = 32 for Glu136Gly, Asp420Val, 
Tyr353Cys and Thr527Met). In addition to analyzing normalized fold 
changes, for each mutant, the mean of the triplicate measures at each 
protein and ATP concentration was compared to that for wild-type protein 
using the Wilcoxon matched-pairs signed-rank test; apart from Asp420Val 
with P = 0.1776 (non-significant), all other mutants were different from  
wild-type protein at P < 0.0001 (significant). 
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In conclusion, we have identified de novo missense mutations 
restricted to the extended ATPase domain of SMCHD1 as the cause 
of isolated arhinia and BAMS. It will be of great interest to explore 
the epistatic relationships between SMCHD1 and known regulators 
of nasal development, such as the PAX6 protein and fibroblast growth 
factor (FGF) and bone morphogenetic protein (BMP) signaling2, as 
well as to uncover other potential human-specific nasal regulators. 
Nose shape and size vary greatly across human populations and 
even more drastically among animal species, with the elephant’s 
trunk being an extreme example. As such, it will be interesting to 
determine the role of SMCHD1 in controlling nose size from an 
evolutionary perspective.
Given that loss-of-function mutations in SMCHD1 are associated 
with FSHD2, BAMS and FSHD2 represent a rare example of different 
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Figure 3 In vivo functional assays in Xenopus embryos suggest that BAMS-associated mutations behave as gain-of-function alleles. (a) Expression of 
smchd1 relative to 18S rRNA by qPCR. Data represent means ± s.d. of triplicates. (b) In late tailbud stages, smchd1 expression is restricted to the 
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V, ventral. (d–f) Representative stage 45 tadpoles that are uninjected (d) or injected with SMCHD1WT (e) or SMCHD1A134S (f) mRNA. Those injected 
with SMCHD1A134S mRNA display craniofacial anomalies and smaller eyes in comparison to control tadpoles and those injected with SMCHD1WT 
mRNA. Scale bar, 0.3 mm. All images were acquired at the same magnification. (g) Immunoblot of stage 12 embryonic extracts from control and 
injected embryos showing expression of exogenous human SMCHD1. (h) Eye diameter is significantly reduced in embryos overexpressing BAMS-
associated mutants (blue) relative to siblings overexpressing wild-type SMCHD1 (black) or embryos overexpressing an FSHD2-associated mutant (open 
circles). (i,j) In situ hybridization for rx2a, six1 and twist1, demarcating the eyes, placodes and neural crest, respectively, in embryos injected with 
SMCHD1WT (i) or SMCHD1A134S (j) mRNA. Images are representative of 9 of 10, 7 of 10, and 10 of 10 embryos for each probe. The dotted lines outline 
nasal placodes (middle) and the eye (right). Numbers label streams of migrating cranial neural crest. Scale bars, 0.2 mm (same magnification for each 
comparison of i to j). (k) Measurements of eye diameter for Xenopus embryos injected with 0.5 or 1 ng of mRNA encoding wild-type SMCHD1 or a 
BAMS-associated mutant show that SMCHD1 overexpression causes dose-dependent craniofacial anomalies. Biological variation between clutches of 
tadpoles is seen in the data presented in h and k. For both h and k, n indicates the number of embryos analyzed, data are shown as means ± s.d. and  
P values were calculated by Kruskal–Wallis test followed by Dunn’s post test.
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functional classes of mutations in the same gene leading to vastly dif-
ferent human disorders, in terms of the affected tissue and age of onset. 
As FSHD is caused in part by loss of SMCHD1, the development of 
drugs that augment the expression or activity of SMCHD1 in affected 
muscles as a form of treatment is currently being pursued (for exam-
ple, by Facio Therapies; see URLs). Our identification of ATPase-
activity-augmenting mutations in SMCHD1 may inform gene therapy 
approaches or, in combination with future structural studies on the 
effect of these mutations on the ATPase domain, aid the design of 
drugs that induce SMCHD1 gain of function, for treatment of FSHD. 
Importantly, for such an approach, the deleterious consequences of 
BAMS-associated SMCHD1 mutations seem to be restricted to a nar-
row window of human embryonic development.
URLs. Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org/; UCSC Genome Browser, http://genome.ucsc.edu/; 
PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/index.shtml; Facio 
Therapies, http://www.facio-therapies.com; LOVD SMCHD1 variant 
database, http://databases.lovd.nl/shared/variants/SMCHD1/unique; 
Eurexpress, http://www.eurexpress.org/ee/intro.html; Phyre2, http://
www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index; PBIL server, 
https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/
npsa_server.html; NHLBI GO Exome Sequencing Project Exome 
Variant Server (EVS), http://evs.gs.washington.edu/EVS/; Exome 
Aggregation Consortium (ExAC) Browser, http://exac.broadinstitute. 
org/; DECIPHER database, https://decipher.sanger.ac.uk; unabridged 
Xenopus protocols, https://sites.google.com/a/reversade.com/www/
protocols/.
MeTHODS
Methods, including statements of data availability and any associated 
accession codes and references, are available in the online version of 
the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINe MeTHODS
Subjects. In all cases, informed consent was obtained from the families for genetic 
testing. For patients in Figure 1, consent to publish photographs was obtained.
Whole-exome sequencing. Whole-exome sequencing was conducted 
in accordance with approved institutional ethical guidelines (Comité de 
Protection des Personnes Ile-de-France II; Ethics Committee of the University 
Hospital Cologne, Germany; National University of Singapore Institutional 
Review Board).
For trio whole-exome sequencing of case 1, Agilent SureSelect libraries were 
prepared using 3 µg of genomic DNA from each individual and sheared with a 
Covaris S2 Ultrasonicator. Exome capture was performed with 51Mb SureSelect 
Human All Exon kit v5 (Agilent Technologies). Sequencing was carried out on 
a pool of barcoded exome libraries using a HiSeq 2500 instrument (Illumina), 
generating 100 + 100 bp paired-end reads. After demultiplexing, paired-end 
sequences were mapped to the reference human genome (GRCh37/hg19 assem-
bly, NCBI) using Burrows–Wheeler aligner (BWA). The mean depth of coverage 
obtained for the three samples from case 1 was 123-fold, 149-fold and 150-fold, 
and 98% of the exome was covered by at least 15-fold. Downstream processing 
was performed using the Genome Analysis Toolkit (GATK)25, SAMtools26 and 
Picard. Variant calls were made with the GATK UnifiedGenotyper. All calls 
with read coverage ≤2-fold or a Phred-scaled SNP quality score of ≤20-fold 
were removed from consideration. Variant annotation was based on Ensembl 
release 71 (ref. 27). Variants were filtered against publicly available SNPs plus 
variant data from more than 7,000 in-house exomes (Institut Imagine).
For trio whole-exome sequencing of case 2, exonic and adjacent intronic 
sequences were enriched from genomic DNA using the NimbleGen SeqCap 
EZ Human Exome Library v2.0 enrichment kit and probes were run on an 
Illumina HiSeq 2000 sequencer at the Cologne Center for Genomics (CCG). 
Data analysis and filtering of mapped target sequences were performed with 
‘Varbank’ exome and genome analysis pipeline v.2.1 (CCG), and data were fil-
tered for high-quality (coverage of more than 6 reads, minimum quality score 
of 10), rare (MAF < 0.5%) autosomal recessive and de novo variants.
For trios of cases 9 and 11 and quartets of cases 10 and 12, whole-exome 
sequencing was performed at the Genome Institute of Singapore. Barcoded 
libraries were prepared for each individual by shearing 1 µg of genomic DNA, 
followed by end repair, A-tailing, adaptor ligation and PCR enrichment, and 
libraries were then pooled and hybridized with NimbleGen SeqCap EZ Human 
Exome Library v3.0 probes. Captured DNA targets were purified and PCR ampli-
fied, and were then sequenced on Illumina HiSeq 2500 (cases 9 and 11) or HiSeq 
4000 (cases 10 and 12) sequencers. Variant calling was performed according 
to the recommended best practices of GATK (v3.4.46). Reads were mapped to 
GRCh37/hg19 using BWA, and the aligned files were preprocessed by Picard and 
GATK25,28,29. All samples were sequenced with mean coverage of 75× or higher. 
Variants were called using GATK HaplotypeCaller along with in-house exomes 
sequenced with the same chemistry. Variants were recalibrated, annotated 
and filtered against in-house data plus common publicly available databases. 
Each family was analyzed independently using Phen-Gen30 for de novo and 
recessive disease inheritance patterns. Variants with alternate allele frequency 
of ≤10 reads or total coverage of ≤20 reads were not considered.
For whole-exome sequencing of case 13, a library was prepared using the 
SureSelect XT Human All Exon v5 kit (Agilent Technologies) according to the 
manufacturer’s instructions, followed by sequencing on a HiSeq 2500 (Illumina) 
sequencer. Raw data files were converted to fastq files with bcl2fastq software 
package version 1.8.4 (Illumina). fastq files were mapped by Novoalign version 3 
(Novocraft) to the hg19 human reference genome sequence. In this step, single- 
nucleotide variant (SNV) information in dbSNP31 build 138 was used for base 
quality score recalibration. Marking of PCR duplicates and position-wise sort-
ing were performed with Novosort version 3 (Novocraft). Calling of SNVs and 
small indels was performed using GATK25,28,29 version 3.4-46. A GATK work-
flow32 was used in which local realignment and variant calling were performed 
by IndelRealigner and HaplotypeCaller, respectively. Low-quality calls for SNVs 
and small indels were removed it they met the following criteria: QD < 2.0, 
MQ < 40.0, FS > 60.0, MQRankSum < −12.5 or ReadPosRankSum < −8.0 
for SNVs; QD < 2.0, ReadPosRankSum < −20.0 or FS > 200.0 for small 
indels. SNVs and small indels were annotated with the ANNOVAR software 
package33 using the following data sets and programs: gene information from 
GENCODE34 (version 19); allele frequencies from the 1000 Genome Project35 
(version August 2015), ExAC (version 0.3; see URLs), EVS (release ESP6500SI-
V2; see URLs) and an in-house database; and predictions of protein damage 
by PolyPhen-2 (ref. 36) and SIFT37 via dbNSFP38,39 (version 3.0).
DNA methylation analysis. DNA methylation was analyzed at single-base 
resolution after sodium bisulfite modification, PCR amplification, cloning and 
Sanger sequencing. Briefly, 2 µg of genomic DNA was denatured for 30 min 
at 37 °C in 0.4 N NaOH and incubated overnight in a solution of 3 M sodium 
bisulfite (pH 5) and 10 mM hydroquinone using a previously described proto-
col40. Converted DNA was then purified using the Wizard DNA CleanUp kit 
(Promega) following the manufacturer’s recommendations and precipitated by 
ethanol precipitation for 5 h at −20 °C. After centrifugation, DNA pellets were 
resuspended in 20 µl of water and stored at −20 °C until use. Converted DNA 
was then amplified using primer sets (Supplementary Table 4) designed with 
MethPrimer software41, avoiding the occurrence of CpGs in primer sequences 
to allow amplification of methylated and unmethylated DNA with the same 
efficiency. Amplification was carried out using High-Fidelity Taq polymerase 
(Roche) according to the manufacturer’s instructions. After initial denatura-
tion at 94 °C for 2 min, amplification was carried out at 94 °C for 20 s, 54 °C for 
30 s, and 72 °C for 1 min for 10 cycles and then at 94 °C for 20 s, 54 °C for 30 
s, and 72 °C for 4.5 min for the first cycle, with the extension step extended by 
30 s for each subsequent cycle, for 25 cycles. At the end of the program, a final 
extension step at 72 °C for 7 min was performed. PCR products were puri-
fied using the Wizard SV Gel and PCR Purification System (Promega), resus-
pended in 50 µl of water and cloned using the pGEM-T Easy Vector cloning kit 
(Promega). Colonies were grown overnight at 37 °C with ampicillin selection, 
and randomly selected colonies were directly PCR amplified using T7 or SP6 
primer. For each sample and region, at least ten randomly cloned PCR prod-
ucts were sequenced according to Sanger’s method by Eurofins MWG Operon 
with either SP6 or T7 primer. Sequences were analyzed using BiQ Analyser 
software42, and the average methylation score was calculated as the number of 
methylated CpGs out of the total number of CpGs in the reference sequence.
Statistics and subjects. The average methylation levels of the groups of sam-
ples (patients with FSHD2 carrying an SMCHD1 mutation, control individuals, 
and patients with BAMS and their relatives) were compared using the Kruskal–
Wallis non-parametric multiple-comparisons test followed by a Dunn’s com-
parison and Bonferroni correction, with α = 0.05. Control individuals (n = 8) 
were healthy donors whom have been previously reported43. The patients 
with FSHD2 carrying an SMCHD1 mutation have previously ben reported43,44 
and comprise n = 8 with methylation data for the DR1 region and n = 15 each 
with methylation data for the 5′ and Mid regions, while for the DR1 region 
21 additional patients for whom sodium bisulfite sequencing data exist in the 
LOVD SMCHD1 variant database (see URLs) were included.
Smchd1–Hsp90 structure modeling and multiple-sequence alignment.  
A homology model of the N-terminal region of Smchd1 was generated using 
the online server Phyre2 (ref. 45). The protein sequence corresponding to amino 
acids 111–702 of mouse Smchd1 was submitted as the input sequence, and inten-
sive modeling mode was selected. The second highest scoring model with the 
most sequence alignment coverage based on the crystal structure of yeast Hsp90 
(Protein Data Bank (PDB) 2CG9) was elected for further evaluation. The model 
was visualized in PyMOL. The multiple-sequence alignment was generated using 
CLUSTAL W (ref. 46; via the PBIL server) and ESPript 3.0 (ref. 47).
ATPase assays. Cloning, expression and purification of recombinant mouse 
Smchd1 protein was performed as previously described22; the sequences of 
the primers used for cloning and mutagenesis are provided in Supplementary 
Table 5. The purity of the protein preparations was assessed by migration of 
samples on 4–20% Tris-glycine reducing SDS–PAGE gels followed by staining 
with SimplyBlue SafeStain (Thermo Fisher Scientific) (Supplementary Fig. 13). 
ATPase assays were performed with the Transcreener ADP2 Fluorescence 
Polarization assay kit (BellBrook Labs) as previously described22. Briefly, 10-µl 
reactions in triplicate were set up in 384-well (low-volume, black) plates, con-
taining 7 µl of reaction buffer (50 mM HEPES (pH 7.5), 4 mM MgCl2 and 
2 mM EGTA), 1 µl of recombinant Smchd1111–702 protein at concentrations 
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ranging from 0.1 to 0.6 µM or buffer control, 1 µl of radicicol or solvent con-
trol, and 1 µl of 10 µM ATP substrate or nuclease-free water control. The 
Hsp90 inhibitor radicicol (Sigma-Aldrich) was dissolved in 70% ethanol and 
further diluted to a final concentration ranging from 0.1 nM to 10 µM. A 12-
point 10 µM ADP/ATP standard curve was set up in parallel. Reactions were 
incubated at room temperature for 1 h in the dark before addition of 10 µl 
of detection mix (1× Stop and Detection Buffer B, 23.6 µg/ml antibody to ADP2) 
and incubation for a further hour. Fluorescence polarization readings were per-
formed with an Envision plate reader (PerkinElmer Life Sciences) following the 
manufacturer’s instructions. The amount of ADP present in each reaction was 
estimated using the standard curve, following the manufacturer’s instructions.
Mouse embryo dissection and X-gal staining. Mice were housed and mouse 
work was performed under approval from the Walter and Eliza Hall Institute 
of Medical Research Animal Ethics Committee (AEC 2014.026). Embryos were 
obtained by mating C57BL/6 Smchd1gt/+ congenic strain sires with C57BL/6 dams, 
with embryo ages ranging from E8.5 to E12.5 (ref. 6). All embryos analyzed were 
female. No randomization or blinding was used during the experimental proce-
dure. Embryos were briefly fixed in 2% paraformaldehyde/0.2% glutaraldehyde 
and stained in 1 mg/ml X-gal for several hours. Cryosections were cut at 12 µm.
Xenopus embryological assays. Xenopus were used according to guidelines 
approved by the Singapore National Advisory Committee on Laboratory 
Animal Research. Protocols for fertilization, injection and whole-mount in situ 
hybridization are available at the protocol website for the Reversade labo-
ratory (see URLs). Human SMCHD1 (Origene) was cloned into the pCS2+ 
expression vector, the vector was linearized with NotI and the insert was 
transcribed with the mMESSAGE mMachine SP6 transcription kit (Thermo 
Fisher). Transcribed mRNA was column purified, and its concentration was 
measured using a Nanodrop instrument. The mRNA contains a poly(A) signal 
that allows for polyadenylation in vivo. To specifically target the cells des-
tined to contribute to anterior head tissue, the two dorsal–animal blastomeres 
were injected at the eight-cell stage with the synthesized mRNA. Embryos 
were allowed to develop at room temperature until they reached stages 45–46 
(4 d.p.f.) and were fixed. Eye diameter was measured using a Leica stereomi-
croscope with a DFC 7000T digital camera. No statistical method was used to 
predetermine sample size. No randomization or blinding was used. Embryos 
that died before gastrulation were excluded. Injections were performed on mul-
tiple clutches to reduce clutch-specific bias. The mRNAs injected for Figure 3k 
did not contain a poly(A) signal and were polyadenylated in vitro, hence 
requiring higher RNA concentrations to produce a phenotype (in other pan-
els in Figure 3 and in Supplementary Figure 12, the mRNAs contained a 
poly(A) signal allowing polyadenylation in vivo). Embryonic extracts were 
prepared by lysing stage 12 embryos in CelLytic Express (Sigma) on ice, fol-
lowed by centrifugation to remove yolk proteins. Extracts were analyzed by 
immunoblotting with antibodies to SMCHD1 (Atlas, HPA039441; 1:500 dilu-
tion) and GAPDH (clone 0411, Santa Cruz Biotechnology; 1:2,000 dilution). 
cDNA was generated from RNA extracted from Xenopus embryos of various 
stages using iScript reverse transcriptase (Bio-Rad). qPCR was performed 
using the primers listed in Supplementary Table 6. The in situ hybridization 
probe for smchd1 was amplified from stage 20 cDNA using the primers listed 
in Supplementary Table 6 and cloned into the pGEM-T vector. The vector 
was linearized, and the insert was transcribed using digoxigenin RNA labeling 
mix (Roche) according to the manufacturer’s guidelines.
DNA damage response assays. Cell lines and cell culture. XRCC4-deficient 
cells48 and primary fibroblast cell lines established from cases 1 and 2 were cul-
tured in DMEM (Gibco) supplemented with 10% FCS (Gibco) and antibiotics. 
Testing for mycoplasma contamination was negative. To assess H2AX activa-
tion, cells were either irradiated with 100 J/m2 UV-C or treated with 50 µM 
etoposide (Sigma-Aldrich) for 1 h. Drugs were then washed out, fresh 
medium was added, and cells were incubated for 6 h and then subjected to 
immunoblot analysis.
Protein isolation and analysis. Cells were solubilized using ice-cold RIPA 
buffer (10 mM Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA, 10 mM NaF, 1 mM 
Na3VO4, 10 µM Na2MoO4, 1% NP-40, 0.25% SDS and protease inhibitors 
P 2714 (Sigma-Aldrich)). The total protein concentration of extracts was 
determined using the BCA Protein Assay kit (Thermo Fisher Scientific). 
Ten micrograms of total cell lysate were separated by 4–12% SDS–PAGE 
(Invitrogen) and blotted onto nitrocellulose membrane (GE Healthcare). 
Protein detection was performed using antibody specific for phosphorylation 
of H2AX at Ser139 (γH2AX) (clone 20E3, Cell Signaling Technology; 1:1,000 
dilution). Antibody to β-actin was purchased from Sigma-Aldrich (clone AC-
74; 1:10,000 dilution). Secondary antibodies conjugated to peroxidase (Santa 
Cruz Biotechnology) were used, and blots were developed using an enhanced 
chemiluminescence system (ECL Plus, GE Healthcare), followed by detection 
of autoradiography by film.
Microhomology-mediated end joining assay. Microhomology-mediated end 
joining (MMEJ) assays using linearized pDVG94 plasmid were performed as 
previously described49. In brief, cells were transfected with 2 µg of pDVG94 
linearized with EcoRV (Thermo Fisher Scientific) and AfeI (New England 
BioLabs), and extrachromosomal DNA was isolated 48 h after transfection. 
PCR analysis was performed, and PCR products were digested using BstXI, sep-
arated by gel electrophoresis and visualized by ethidium bromide staining.
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in the European Genome-phenome Archive (EGA) under accessions 
EGAS00001002193.
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